NCT04993404View on ClinicalTrials.gov

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions
Hepatic InsufficiencyHealthy Subjects
Interventions
DRUG

Jaktinib Hydrochloride Tablets

A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04993404 - Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function | Biotech Hunter | Biotech Hunter